Worldwide Specialty Chemicals (ZECI) 10-K 18 Jul 18 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2017	Jul. 09, 2018	Jun. 30, 2017
Document And Entity Information
Entity Registrant Name	Worldwide Specialty Chemicals Inc.
Entity Central Index Key	1,660,156
Document Type	10-K
Document Period End Date	Dec. 31, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	No
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 0
Entity Common Stock, Shares Outstanding		24,855,893
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,017

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2017	Dec. 31, 2016
CURRENT ASSETS
Cash and cash equivalents	$ 275,886	$ 50,202
Accounts receivable	49,603	13,600
Inventory	62,541	7,684
Prepaid expenses	8,205	5,742
Employee advance	31,102	0
Total current assets	427,337	77,228
Goodwill	2,294,952	0
Vehicles and trailers	223,413	0
Equipment	420,004	0
Leasehold improvements	28,855	0
Total fixed assets	672,272	0
Accumulated depreciation	(83,288)	0
Fixed assets, net	588,984	0
TOTAL ASSETS	3,311,273	77,228
CURRENT LIABILITIES
Accounts payable	224,244	81,939
Accrued expenses	19,949	39,022
Due to CBI	4,463	1,667
Notes payable - current portion	35,650	900,187
Total current liabilities	284,306	1,022,815
LONG TERM LIABILITIES
Notes payable	73,662	0
TOTAL LIABILITIES	357,968	1,022,815
Commitments and Contingencies
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred stock, $0.0001 par value, 20,000,000 shares authorized; no shares issued or outstanding	0	0
Common stock, $0.0001 par value, 100,000,000 shares authorized; 24,300,326 issued and outstanding as of December 31, 2017 and 6,817,393 issued and outstanding as of December 31, 2016	2,430	682
Additional paid-in capital	7,661,882	1,049,773
Accumulated deficit	(4,711,007)	(1,996,042)
TOTAL STOCKHOLDERS' EQUITY (DEFICIT)	2,953,305	(945,587)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	$ 3,311,273	$ 77,228

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Common stock authorized	100,000,000	100,000,000
Common stock par value	$ .0001	$ .0001
Common stock issued	24,300,326	6,817,393
Common stock outstanding	24,300,326	6,817,393
Preferred stock authorized	20,000,000	20,000,000
Preferred stock par value	$ .0001	$ .0001
Preferred stock issued	0	0
Preferred stock outstanding	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Statement [Abstract]
Revenues	$ 1,141,209	$ 40,014
Cost of goods sold	641,462	6,517
Gross profit	499,747	33,497
Operating expenses
General and administrative	2,752,486	924,478
Selling	144,065	118,280
Depreciation	83,288	0
License impairment	0	843,151
Total operating expenses	2,979,839	1,885,909
Other income and (loss)
Interest income	(32)	(4)
Interest expense	234,905	60,315
Other expense	0	2,710
Total other expense	234,873	63,021
Net loss	$ (2,714,965)	$ (1,915,433)
Basic and diluted - loss per share	$ (0.31)	$ (0.41)
Weighted average shares - basic and diluted	8,822,360	4,617,918

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($)	Common Stock	Additional Paid-In Capital	Retained Earnings / Accumulated Deficit	Total
Beginning balance, shares at Dec. 31, 2015	3,580,000
Beginning balance, value at Dec. 31, 2015	$ 358	$ 0	$ (80,609)	$ (80,251)
Common stock issued for license agreement, shares	500,000
Common stock issued for license agreement, value	$ 50			50
Notes payable converted to common stock, shares	2,737,393
Notes payable converted to common stock, value	$ 274	1,049,773		1,050,047
Net loss			(1,915,433)	(1,915,433)
Ending balance, shares at Dec. 31, 2016	6,817,393
Ending balance, value at Dec. 31, 2016	$ 682	1,049,773	(1,996,042)	(945,587)
Notes payable converted to common stock, shares	3,877,931
Notes payable converted to common stock, value	$ 388	361,072		3,614,760
Common stock issued for acquisition, shares	520,000
Common stock issued for acquisition, value	$ 52	7,748		7,800
Common stock issued for services, shares	9,400,000
Common stock issued for services, value	$ 940	611,860		912,800
Common stock issued new, shares	1,183,334
Common stock issued new, value	$ 118	887,382		887,500
Warrants exercised, stock issued	2,375,000
Warrants exercised, value	$ 237	1,187,263		$ 1,187,500
Options exercised, shares issued	126,668			126,668
Options exercised, value	$ 13	189,987		$ 190,000
Share based compensation		96,797		96,797
Net loss			(2,714,965)	(2,714,965)
Ending balance, shares at Dec. 31, 2017	24,300,326
Ending balance, value at Dec. 31, 2017	$ 2,430	$ 7,661,882	$ (4,711,007)	$ 2,953,305

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Cash Flows from Operating Activities
Net loss	$ (2,714,965)	$ (1,915,433)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	83,288	843,151
Allowance for doubtful accounts	238,306	0
Interest expense accrued	231,272	60,315
Share based compensation	96,797	0
Common stock issued for services	612,800	0
Change in current assets and current liabilities
Accounts receivable	(233,875)	(12,245)
Inventory	(16,357)	(7,684)
Prepaid expenses	(2,463)	(5,742)
Other current assets	(31,102)	0
Accounts payable and accrued expenses	82,607	83,461
Due to CBI	2,796	(128,298)
Net cash used in operating activities	(1,650,896)	(1,082,475)
Cash Flows from Investing Activities
Acquisition, net of cash acquired	(1,128,954)	0
Purchase of property and equipment	(184,277)	0
Total cash used in investing activities	(1,313,231)	0
Cash Flows from Financing Activities
Proceeds from notes payable	2,500,000	1,395,000
Payments on notes payable	(1,575,189)	(262,500)
Proceeds from sale of common stock	2,265,000	50
Net cash provided by financing activities	3,189,811	1,132,550
Total increase in cash and cash equivalents	225,684	50,075
Cash and cash equivalents at beginning of year	50,202	127
Cash and cash equivalents at end of year	275,886	50,202
NON CASH INVESTING & FINANCING ACTIVITIES
Acquisition of licenses under long term financing agreements	0	1,440,000
Notes payable and accrued interest converted to common stock	3,631,460	1,050,047
Convertible promissory notes assumed from CBI	0	494,919
Property and equipment purchased under financing agreements	29,916	0
Acquisition under a short term promissory note	2,700,000	0
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Cash paid for Interest	3,632	0
Cash paid for taxes	$ 0	$ 0

Nature of Business

Nature of Business	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Nature of Business	NATURE OF BUSINESS Worldwide Specialty Chemicals Inc. (“WSC”), a Delaware corporation formed in March of 2014 and based in downtown Dallas, Texas, is an international specialty chemical company with many products that are friendly to the environment. On February 15, 2017, WSC acquired 100% ownership of KT Chemicals, Inc. (“KT Chemicals” or “KT” ), a Texas corporation founded in February 2014 (WSC and KT are collectively referred to as the “Company”). KT is also a specialty chemicals company, serving as both manufacturer and distributor of environmentally safe, specialty chemicals. KT is located at 1002 North Central Expressway, Suite 499, Richardson, Texas 75080. The Company’s products are used in a diverse array of applications, including: • Military weapons and Department of Energy Decommissioning and Decontamination (D&D) sites • Military Chemical, Biological, Radiological, Nuclear, and Explosives (CBRNE) sites • Commercial nuclear power plants and nuclear powered ships • Nuclear medicine and research laboratory environments using radioisotopes and hazardous chemicals and substances • Hazardous toxic industrial chemical and toxic industrial material clean-up KT’s products utilize all-natural and renewable resources, contain no dangerous chemicals or additives, and offer “green” solutions to its customers. KT’s product line includes asphalt release agents, industrial cleaners, environmental remediation gels, odor control agents, and consumer friendly cleaners for a wide range of uses, including construction, environmental remediation, hazardous materials clean-up, nuclear decommissioning, industrial cleaning, and odor control. The Company currently operates from several corporate and subsidiary offices around the country. The Company also operates from a 20,000 square foot chemical production and distribution facility, from which it markets a number of specialty chemicals.

1. Summary of Significant Accou

1. Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES A summary of the significant accounting polices consistently applied in the preparation of the accompanying consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (“GAAP”) is as follows. Basis of Consolidation The consolidated financial statements include the accounts of KT Chemicals, Inc. since the date of acquisition. All significant intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Fair Value of Financial Instruments FASB ASC 825-10 requires disclosure of fair value information about certain financial instruments, including, but not limited to, cash and cash equivalents, accounts receivable, prepaid expenses, accounts payable, accrued expenses and notes payable. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management at December 31, 2017 and 2016. The carrying value of the financial instruments included in the Company’s consolidated financial statements approximated their fair values. The carrying value of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities are carried at, or approximate, fair value as of the reporting date because of their short-term nature. The carrying value of the notes payable approximates fair value as they bear market rates of interest. Basic and Diluted Net Loss Per Share Basic net loss per share is computed using the weighted average number of common shares outstanding. Diluted loss per share has not been presented because there are no dilutive items. Diluted earnings loss per share is based on the assumption that all dilutive stock options, warrants, and convertible debt are converted or exercised by applying the treasury stock method. Under this method, options and warrants are assumed exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. Options, warrants and/or convertible debt will have a dilutive effect, during periods of net profit, only when the average market price of the common stock during the period exceeds the exercise or conversion price of the items. For the years ended December 31, 2017 and 2016, approximately 1,110,000 and 2,885,000 common stock warrants, respectively, and 3,439,750 and 0 common stock options, respectively, were not added to the diluted average shares because inclusion of such warrants would be antidilutive. Cash and Cash Equivalents The Company considers all highly liquid investments with an initial maturity of three months or less, when purchased, to be cash equivalents. The Company maintains cash balances at several financial institutions located throughout the United States, which at times may exceed insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk on cash and cash equivalents. Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at invoiced amount and generally do not bear interest. An allowance for doubtful accounts is established, as necessary, based on past experience and other factors which, in management's judgment, deserve current recognition in estimating bad debts. Such factors include growth and composition of accounts receivable, the relationship of the allowance for doubtful accounts to accounts receivable, and current economic conditions. The determination of the collectability of amounts due requires the Company to make judgments regarding future events and trends. Allowances for doubtful accounts are determined based on assessing the Company’s portfolio on an individual customer and on an overall basis. This process consists of a review of historical collection experience, current aging status of the customer account, and the financial condition of the Company’s customers. Based on a review of these factors, the Company establishes or adjusts the allowance for specific customers and the accounts receivable portfolio as a whole. At December 31, 2017 and 2016, the allowance for doubtful accounts was $0. Revenue Recognition The Company recognizes revenue in accordance with ASC topic 605, “Revenue Recognition, and other applicable revenue recognition guidance under US GAAP. During 2017, revenue reported by the Company was for product sales and is recognized when: (i) persuasive evidence of a sales arrangement exists, (ii) the sales terms are fixed or determinable, (iii) title and risk of loss have transferred, and (iv) collectability is reasonably assured. During 2016, revenue is for commissions earned on product sales under agreements with KT Chemicals and is recognized when: (i) persuasive evidence of a sales arrangement exists, (ii) the sales terms are fixed or determinable, (iii) title and risk of loss have transferred, and (iv) collectability is reasonably assured. Revenue related to license agreements are recognized once earned in accordance with the applicable license agreement. During the year ended December 31, 2016, 100% of the Company’s revenue was related to the license agreement with KT Chemicals. Inventory Inventory is stated at the lower of cost or net realizable value, with cost determined on a first-in first-out basis. The carrying value of inventory is reduced for estimated obsolescence. The Company evaluates the inventory carrying value for potential excess and obsolete inventory exposures by analyzing historical and anticipated demand. The following table sets forth the components of the Company’s inventory balances as of December 31: 2017 2016 Finished goods $ 22,753 $ 7,684 Raw materials 35,557 – Packaging supplies 4,231 – $ 62,541 $ 7,684 Fixed Assets Fixed assets consist of furniture, fixtures and office equipment, vehicles and trailers, equipment and leasehold improvements that are stated at cost, less accumulated depreciation. Depreciation is provided in amounts sufficient to relate the cost of depreciable assets to earnings over their estimated service lives (3 – 10 years) under the straight-line method. Maintenance and repairs are charged to earnings as incurred; major repairs and replacements are capitalized. When items of property or equipment are sold or retired, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is included in operations. Property and equipment operated under material leases which transfer substantially all benefits and risks associated with the assets to the Company are capitalized. An asset and liability equal to the present or fair value, if appropriate, of minimum payments over the term of the leases are recorded. Depreciation of the asset is computed using the straight-line method over the life of the asset. Expenses associated with operating leases are charged to income as incurred. Goodwill Goodwill represents the excess of the value of the purchase price and related costs over the identifiable assets from business acquisitions. The Company conducts an annual impairment assessment, at the reporting unit level, of its recorded goodwill. The Company assesses qualitative factors in order to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. The qualitative factors evaluated by the Company include: macro-economic conditions of the local business environment, overall financial performance, and other entity specific factors as deemed appropriate. If, through this qualitative assessment, the conclusion is made that it is more likely than not that a reporting unit’s fair value is less than its carrying amount, a two-step impairment test is performed. Management determined, by assessing the qualitative factors, that it is more likely than not that the fair value of the reporting unit is greater than its carrying value. Management does not consider the value of goodwill recorded for KT in the accompanying consolidated balance sheet to be impaired as of December 31, 2017. (see Note 10) The accompanying consolidated balance sheets, consolidated statements of operations, changes in stockholders’ equity (deficit) and cash flows include the results of operations of KT from the date of acquisition. Goodwill consists of the following: Goodwill at December 31, 2016 $ – Goodwill generated from acquisition of KT 2,294,952 Goodwill at December 31, 2017 $ 2,294,952 Share-Based Compensation The Company recognizes compensation expense for all share-based payments in accordance with FASB Codification Topic 718, Compensation — Stock Compensation Income Taxes The Company accounts for Federal and state income taxes using the asset and liability approach for financial accounting and reporting for income taxes based on tax effects of differences between the financial statement and tax basis of assets and liabilities. The Company accounts for all uncertain tax positions in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification 740 – Income Taxes (“ASC 740”). ASC 740 provides guidance on de-recognition, classification, interest and penalties and disclosure related to uncertain income tax positions. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as a component of income tax expense. There were no accrued interest or penalties as of December 31, 2017 and 2016. From time to time, the Company may be audited by taxing authorities. These audits could result in proposed assessments of additional taxes. The Company believes that its tax positions comply in all material respects with applicable tax law. However, tax law is subject to interpretation, and interpretations by taxing authorities could be different from those of the Company, which could result in the imposition of additional taxes. The Company’s federal returns since 2014 are still subject to examination by taxing authorities. Prepaid Expenses Prepaid expenses consist of expenses the Company has paid for prior to the service or good being provided. These prepaid expenses will be recorded as expense at the time the service has been provided. License Fee Effective December 31, 2016, the Company entered into an Exclusive Patent Licenses Agreement with CBI Polymers, Inc. ("CBI"), pursuant to which the Company would sell DeconGel ™ Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred substantial operating losses during 2017 and 2016 resulting in an accumulated deficit of $4,711,007 at December 31, 2017, and an accumulated deficit of $1,996,042 and a deficit in equity of $945,587 at December 31, 2016. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the financial statements are being issued. As such, the Company will need to arrange for additional financing to fully implement its business plan, including continued growth and establishment of a stronger brand. The Company is actively seeking growth of its service offerings, both organically and via new client relationships. In the ordinary course of the Company’s business, management is trying to raise additional capital through sales of common stock as well as seeking debt financing from third parties. There are no assurances that additional financing will be available on favorable terms, or at all. If additional financing is not available, the Company will need to reduce, defer or cancel development programs, planned initiatives and overhead expenditures. The failure to adequately fund its capital requirements could have a material adverse effect on the Company’s business, financial condition and results of operations, including potential discontinuance of operations. Moreover, the sale of additional equity securities to raise financing will result in additional dilution to the Company’s stockholders. Additionally, incurring additional indebtedness could involve an increased debt service cash obligation, as well as the imposition of covenants that restrict the Company’s operations or the Company’s ability to perform on its current debt service requirements. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Recently Issued Accounting Pronouncements Pronouncements Recently Adopted In July 2015, the Financial Accounting Standards Board (“FASB”) issued an Accounting Standards Update (“ASU”) No. 2015-11, Simplifying the Measurement of Inventory In November 2015, the FASB issued ASU No. 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes In March 2016, the FASB issued ASU No. 2016-09, Compensation – Stock Compensation (Topic 718) Pronouncements Not Yet Adopted In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, In February 2016, the FASB issued ASU Update No. 2016-02, Leases (Topic 842) In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments - a consensus of the Emerging Issues Task Force certain transactions are classified in the statement of cash flows. Certain issues addressed in this guidance include - debt payments or debt extinguishment costs, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, distributions received from equity method investments and beneficial interests in securitization transactions. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. ASU 2016-15 is not expected to have a material impact on the Company’s consolidated financial statements. In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business ASU 2017-01 is not expected to have a material impact on the Company’s consolidated financial statements. In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill impairment On May 10, 2017, the FASB issued ASU No. 2017-09, Compensation–Stock Compensation (Topic 718): Scope of Modification Accounting

2. Accounts Receivable

2. Accounts Receivable	12 Months Ended
	Dec. 31, 2017
Receivables [Abstract]
Accounts Receivable	2. ACCOUNTS RECEIVABLE Accounts receivable relate to trade receivables from product sales and commissions earned on sales made by the Company. Accounts receivable consist of the following at December 31: 2017 2016 Commissions receivable from KT (prior to acquisition) $ – $ 13,600 Trade receivables 49,603 – $ 49,603 $ 13,600

3. Due To_From CBI

3. Due To/From CBI	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Due To/From CBI	3. DUE TO / FROM CBI At December 31, 2017 and 2016, the Company owed CBI $4,463 and $1,667, respectively for license fees payable related to the Company's Exclusive Patent License Agreement with CBI.

4. Notes Payable

4. Notes Payable	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Notes Payable	4. NOTES PAYABLE Convertible Promissory Notes Payable During 2016, the Company received $1,010,000 from several individuals in exchange for convertible promissory notes. These notes are convertible at the election of the Holder at any time after issuance or at the election of the Company at maturity date by dividing the principal and accrued interest by conversion prices ranging between $0.30 and $0.40. The rate for these newly-issued notes is 12% and each note had a maturity date of December 31, 2016. On September 30, 2016, these notes were converted into 2,737,393 shares of common stock valued at $1,050,047. On October 5, 2016, the Company assumed $494,919 of convertible promissory notes from CBI. The notes are convertible into shares of the Company's common stock at the election of the Holder at any time after issuance, or at the election of the Company at maturity date. The number of shares issuable upon conversion is determined by dividing the principal and accrued interest by $0.40. The interest rate for these issued notes is 12% and each note has a maturity date of December 31, 2016. The maturity date of these notes was extended to June 30, 2017. On July 1, 2017, the notes went into default and as a result, accrued interest at the default interest rate of 15%. The principal and accrued interest balance of these notes at December 31, st nd Effective December 31, 2017, the Company issued a total of 3,877,931 common shares as settlement of all outstanding convertible promissory notes payable, having principal and accrued interest totaling $3,631,460. The conversion of the outstanding debt and accrued interest cured the events of default under such debt instruments. Acquisition Note Payable On February 15, 2017, the Company issued a short term promissory note to KT Chemicals stockholders in the amount of $2,700,000, of which $1,150,000 was paid on the acquisition date. The note was due on December 31, 2017. During 2017, the Company paid the note in full. Vehicles and Equipment Notes Payable The Company has three notes payable with separate financial institutions relating to the purchase of certain of the Company’s vehicles and equipment. The balance outstanding under these notes payable was $109,312 and $0 at December 31, 2017 and 2016, respectively. The notes payable bear interest ranging from 3.95% - 5.99% with principal and interest due monthly. The notes mature in July 2020, December 2020 and February 2021. The Company’s future minimum principal payments as of December 31, 2017 are as follows: 2018 $ 35,650 2019 37,251 2020 34,292 2021 2,119 2022 and thereafter – $ 109,312

5. Accrued Expenses

5. Accrued Expenses	12 Months Ended
	Dec. 31, 2017
Payables and Accruals [Abstract]
Accrued Expenses	5. ACCRUED EXPENSES Accrued expenses consist of the following at December 31: 2017 2016 Professional Fees $ – $ 38,000 Other Accrued Expenses 19,949 1,022 $ 19,949 $ 39,022

6. Income Taxes

6. Income Taxes	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	6. INCOME TAXES On December 22, 2017, the Tax Cuts and Jobs Act (the “Act”) was signed into United States tax law, which among other provisions lowered the corporate tax rate to 21%. Given this date of enactment, the Company’s consolidated financial statements as of and for the year ended December 31, 2017 reflect the impact of the Act. The Company elected C Corporation tax status upon inception in 2014. Net operating losses (“NOL”) since that date total $4,933,788 as of December 31, 2017 and may be carried forward to offset future taxable income. As future taxable income is uncertain, a full valuation allowance has been recorded and accordingly, no current provision for income tax has been recorded in the accompanying statements of operations. NOL carry-forward benefits begin to expire in 2035. The following table summarizes the difference between the actual tax provision and the amounts obtained by applying the statutory tax rates to the income or loss before income taxes for the years ended December 31: 2017 2016 Tax benefit calculated at statutory rate 21% 34% Expense not deductible (.19 ) (0.15 ) Changes to valuation allowance (11.29 ) (33.85 ) Effect of U. S. Statutory rate changes (9.52 ) – Provision for income taxes –% –% A deferred tax liability or asset is determined based on the difference between the financial statement and tax bases of assets and liabilities as measured by the enacted tax rates which will be in effect when these differences reverse. Deferred tax expense or benefit in the accompanying consolidated statements of operations are the result of changes in the assets and liabilities for deferred taxes. The measurement of deferred tax assets is reduced, if necessary, by the amount for any tax benefits that, based on available evidence, are not expected to be realized. Income tax expense is the current tax payable or refundable for the year plus or minus the net change in the deferred tax assets and liabilities. Deferred income taxes of the Company arise from the temporary differences between financial statement and income tax recognition of NOL carry-forwards. The deferred tax assets and liabilities in the accompanying consolidated balance sheets include the following components at December 31: 2017 2016 Net non-current deferred tax assets: Net operating loss carry-forward $ 1,036,096 $ 675,696 Fixed assets 24,079 – Net non-current deferred tax liabilities: Intangible assets (10,841 ) – Net 1,049,333 675,696 Less valuation allowance (1,049,333 ) (675,696 ) Net deferred taxes $ – $ – The change in valuation allowance of $373,637 was driven primarily by the current year loss and the change in statutory rate.

7. Commitments, Contingencies a

7. Commitments, Contingencies and Concentrations	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments, Contingencies and Concentrations	7. COMMITMENTS, CONTINGENCIES AND CONCENTRATIONS Leases The Company leases various office space on a month to month basis. Rental expense for the year ended December 31, 2017 and 2016 was $99,750 and $23,512, respectively. Concentrations As of December 31, 2016, the entire balance in accounts receivable represents commissions due from KT Chemicals (prior to its acquisition) and license fees due from CBI. At December 31, 2016, the Company's revenues consisted 100% of commissions due from KT Chemicals and license fees due from CBI.

8. Stockholders' Equity

8. Stockholders' Equity	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Stockholders' Equity	8. STOCKHOLDERS’ EQUITY Common and Preferred Stock As of December 31, 2017 and 2016, the authorized share capital of the Company consisted of 100,000,000 shares of common stock with $0.0001 par value, and 20,000,000 shares of preferred stock also with $0.0001 par value. No other classes of stock are authorized. Warrants During 2014, under the previous management, prior to the current change of control, the Company distributed two million five hundred thousand warrants in the Company to all of its previous creditors of the Company. The creditors received five warrants in the Company for each $0.10 of the Company’s previous administrative debt which they held. These creditors received an aggregate of 2,500,000 warrants consisting of 500,000 “A Warrants” each convertible into one share of common stock at an exercise price of $4.00; 500,000 “B Warrants” each convertible into one share of common stock at an exercise price of $5.00; 500,000 “C Warrants” each convertible into one share of common stock at an exercise price of $6.00; 500,000 “D Warrants” each convertible into one share of common stock at an exercise price of $7.00; and 500,000 “E Warrants” each convertible into one share of common stock at an exercise price of $8.00. All warrants are exercisable at any time prior to August 30, 2017. All warrants expired in August of 2017. As set forth in Note 4 there were $2,885,000 in notes payable issued. These notes came with one warrant for each dollar borrowed for a total 2,885,000 warrants at an exercise price of $0.50, all of which expire on December 31, 2017. On February 9, 2018, the expiration date of the warrants was extended to December 31, 2018 (see Note 11). The fair value of these warrants upon issuance was $0. On March 31, 2017, the Company issued 600,000 warrants at an exercise price of $.50 for services provided to a consultant. The warrants expire on March 31, 2024. The fair value of these warrants upon issuance was $302. There were 2,375,000 warrants exercised during the year ended December 31, 2017 at $.50 per share for a total cash amount of $1,187,500. As of December 31, 2017 and 2016, there were 1,110,000 and 2,885,000 common stock warrants outstanding, respectively, with an exercise price of $.50. See Note 11 for additional warrants exercised subsequent to December 31, 2017. Stock option plan Effective February 1, 2017, the Company established the 2016 Stock Option Plan (the “Plan”). The Board of Directors of the Company has the authority and discretion to grant stock options. The maximum number of shares of stock that may be issued pursuant to the exercise of options under the Plan is 2,000,000. Eligible individuals include any employee or director of the Company and any consultant providing services to the Company. The expiration date and exercise price for each stock option grant are as established by the Board of Directors of the Company. No option may be issued under the Plan after February 1, 2027. On December 28, 2017, the Plan was amended to increase the maximum number of shares of stock that may be issued to 3,750,000. Stock option activity during the year ended December 31, 2017 is summarized as follows: Shares Under Option Price Per Share Weighted Average Exercise Price Weighted Average Remaining Contractual Life Outstanding - beginning of year – $ – $ – Granted 3,566,418 $ 0.00 - 1.50 $ 0.39 Exercised 126,668 $ 1.50 $ 1.50 Canceled or expired – – – Outstanding - end of year 3,439,750 $ 0.00 - 1.50 $ 0.39 113 months Exercisable - end of year 2,827,417 $ 0.42 113 months The fair value of each option grant is calculated using the following assumptions: 2017 Expected life – years 3.25 – 10 Interest rate 1.50 - 2.48 % Volatility 71.70 % Dividend yield – % Total share based compensation expense (including stock grants) included in salaries and wages was $709,597 for the year ended December 31, 2017. Unamortized share-based compensation expense as of December 31, 2017 amounted to $10,548 which is expected to be recognized over the next 20 months.

9. Related Party Transactions

9. Related Party Transactions	12 Months Ended
	Dec. 31, 2017
Related Party Transactions [Abstract]
Related Party Transactions	9. RELATED PARTY TRANSACTIONS Throughout 2017, the Company incurred consulting fees of $299,710 to three current shareholders. The unpaid balance due was $77,000 as of December 31, 2017 and is included in accounts payable in the accompanying consolidated financial statements. The Company is in effect a sales representative of CBI pursuant to the Exclusive Patent License Agreement between the Company and CBI. CBI and the Company are companies under the common control of E. Thomas Layton, the Company’s chairman and chief executive officer. There are no other transactions or contracts between CBI and the Company other than those discussed in this report. The Company was also a sales representative of KT Chemicals, Inc., which was partially owned by E. Thomas Layton until immediately prior to the Company’s acquisition of KT (see Note 10). Throughout 2016, the Company paid consulting fees of $21,503 to a company named Maine Consultants Inc. owned by the spouse of E. Thomas Layton. As of October 2016, the Company no longer relied on Maine for any consulting services. Throughout 2016, the Company incurred consulting fees of $80,000 to a former executive and current shareholder. The unpaid balance due was $25,000 and $80,000 as of December 31, 2017 and 2016, respectively and is included in accounts payable in the accompanying consolidated financial statements.

10. Business Acquisition

10. Business Acquisition	12 Months Ended
	Dec. 31, 2017
Business Combinations [Abstract]
Business Acquisition	10. BUSINESS ACQUISITION Effective February 15, 2017, the Company completed the acquisition of KT Chemicals, Inc., a specialty chemicals company located in Richardson, Texas. Under the terms of the acquisition, the Company acquired 100% of KT Chemicals’ stock for cash and stock. The Company agreed to pay to KT Chemicals stockholders $2,700,000 in cash by December 31, 2017 and issue 520,000 shares of the Company’s common stock valued at $0.015 per share for a total stock value of $7,800 in exchange for all outstanding shares of KT Chemicals’ common stock. The primary asset acquired from KT Chemicals is the expertise of KT, which the Company believes it will be able to leverage in maximizing the sales of specialty chemicals on a go forward basis. As of February 15, 2017, these factors contributed to a purchase price in excess of the fair value of KT Chemicals’ tangible assets acquired, and, as a result, the Company has recorded goodwill in the amount of $2,294,952 in connection with this transaction. Goodwill, as a result of this acquisition, is not deductible for tax purposes. The Company is in the process of finalizing the purchase price allocation and accordingly, the preliminary allocation of the purchase price is subject to adjustment. The transaction resulted in recording assets, liabilities and goodwill at preliminary estimated fair value as follows: Total consideration $ 2,707,800 The assets acquired and liabilities assumed were as follows: Assets acquired: Cash $ 21,046 Inventory 38,500 Accounts receivable 40,434 Property and equipment, net 458,079 Total tangible assets 558,059 Liabilities assumed: Accounts payable 28,932 Accrued expenses 11,693 Capital lease 104,586 Total liabilities 145,211 Net acquired assets 412,848 Goodwill 2,294,952 Total $ 2,707,800 The following table presents selected unaudited pro forma information assuming the acquisition of KT Chemicals had occurred on January 1, 2016. Pro Forma Information (unaudited) December 31, 2017 December 31, 2016 Revenues $ 1,179,456 $ 755,660 Net loss $ (2,783,694 ) $ (2,234,996 ) Loss per share $ (.31 ) $ (.48 ) The unaudited pro forma revenue and pro forma net loss are not necessarily indicative of the consolidated results of operations for the future periods or the results of operations that would have been realized had the Company consolidated KT Chemicals during the period noted.

11. Subsequent Events

11. Subsequent Events	12 Months Ended
	Dec. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	11. SUBSEQUENT EVENTS On February 9, 2018, the Plan was amended to increase the maximum number of shares of stock that may be issued to 4,500,000. It was further amended on March 18, 2018 to increase the maximum number of shares of stock that may be issued to 5,000,000 On January 3, 2018, 80,000 warrants were exercised at $.50 per share for a total cash amount of $40,000. On February 9, 2018, the expiration date of the remaining warrants was extended to December 31, 2018. On February 28, 2018, the Company sold 33,333 common shares at $1.50 per share for a total cash amount of $50,000. On March 2, 2018, the Company sold 16,500 common shares at $1.50 per share for a total cash amount of $24,750. On March 14, 2018, the Company sold 50,000 common shares at $1.50 per share for a total cash amount of $75,000. On March 16, 2018, the Company sold 10,000 common shares at $1.50 per share for a total cash amount of $15,000. On March 19, 2018, the Company sold 100,000 common shares at $1.50 per share for a total cash amount of $150,000. On April 2, 2018, the Company sold 6,667 common shares at $1.50 per share for a total cash amount of $10,000. On April 13, 2018, the Company sold 13,400 common shares at $1.50 per share for a total cash amount of $20,100. On April 30, 2018, the Company sold 34,000 common shares at $1.50 per share for a total cash amount of $51,000. On May 4, 2018, 15,000 warrants were exercised at $.50 per share for a total cash amount of $7,500. On May 4, 2018, 10,000 warrants were exercised at $.50 per share for a total cash amount of $5,000. On May 18, 2018, the Company sold 13,000 common shares at $1.50 per share for a total cash amount of $19,500. On May 19, 2018, 39,000 warrants were exercised at $.50 per share for a total cash amount of $19,500. On May 21, 2018, 15,000 warrants were exercised at $.50 per share for a total cash amount of $7,500. On May 24, 2018, the Company sold 5,000 common shares at $1.50 per share for a total cash amount of $7,500. On June 7, 2018, the Company sold 6,667 common shares at $1.50 per share for a total cash amount of $10,000. On June 15, 2018, the Company sold 34,000 common shares at $1.50 per share for a total cash amount of $51,000. On June 26, 2018, 40,000 warrants were exercised at $.50 per share for a total cash amount of $20,500. On June 28, 2018, the Company sold 34,000 common shares at $1.50 per share for a total cash amount of $51,000.

1. Summary of Significant Acc19

1. Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Basis of Consolidation	Basis of Consolidation The consolidated financial statements include the accounts of KT Chemicals, Inc. since the date of acquisition. All significant intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Fair Value of Financial Instruments	Fair Value of Financial Instruments FASB ASC 825-10 requires disclosure of fair value information about certain financial instruments, including, but not limited to, cash and cash equivalents, accounts receivable, prepaid expenses, accounts payable, accrued expenses and notes payable. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management at December 31, 2017 and 2016. The carrying value of the financial instruments included in the Company’s consolidated financial statements approximated their fair values. The carrying value of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities are carried at, or approximate, fair value as of the reporting date because of their short-term nature. The carrying value of the notes payable approximates fair value as they bear market rates of interest.
Basic and Diluted Net Loss Per Share	Basic and Diluted Net Loss Per Share Basic net loss per share is computed using the weighted average number of common shares outstanding. Diluted loss per share has not been presented because there are no dilutive items. Diluted earnings loss per share is based on the assumption that all dilutive stock options, warrants, and convertible debt are converted or exercised by applying the treasury stock method. Under this method, options and warrants are assumed exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. Options, warrants and/or convertible debt will have a dilutive effect, during periods of net profit, only when the average market price of the common stock during the period exceeds the exercise or conversion price of the items. For the years ended December 31, 2017 and 2016, approximately 1,110,000 and 2,885,000 common stock warrants, respectively, and 3,439,750 and 0 common stock options, respectively, were not added to the diluted average shares because inclusion of such warrants would be antidilutive.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with an initial maturity of three months or less, when purchased, to be cash equivalents. The Company maintains cash balances at several financial institutions located throughout the United States, which at times may exceed insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk on cash and cash equivalents.
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at invoiced amount and generally do not bear interest. An allowance for doubtful accounts is established, as necessary, based on past experience and other factors which, in management's judgment, deserve current recognition in estimating bad debts. Such factors include growth and composition of accounts receivable, the relationship of the allowance for doubtful accounts to accounts receivable, and current economic conditions. The determination of the collectability of amounts due requires the Company to make judgments regarding future events and trends. Allowances for doubtful accounts are determined based on assessing the Company’s portfolio on an individual customer and on an overall basis. This process consists of a review of historical collection experience, current aging status of the customer account, and the financial condition of the Company’s customers. Based on a review of these factors, the Company establishes or adjusts the allowance for specific customers and the accounts receivable portfolio as a whole. At December 31, 2017 and 2016, the allowance for doubtful accounts was $0.
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with ASC topic 605, “Revenue Recognition, and other applicable revenue recognition guidance under US GAAP. During 2017, revenue reported by the Company was for product sales and is recognized when: (i) persuasive evidence of a sales arrangement exists, (ii) the sales terms are fixed or determinable, (iii) title and risk of loss have transferred, and (iv) collectability is reasonably assured. During 2016, revenue is for commissions earned on product sales under agreements with KT Chemicals and is recognized when: (i) persuasive evidence of a sales arrangement exists, (ii) the sales terms are fixed or determinable, (iii) title and risk of loss have transferred, and (iv) collectability is reasonably assured. Revenue related to license agreements are recognized once earned in accordance with the applicable license agreement. During the year ended December 31, 2016, 100% of the Company’s revenue was related to the license agreement with KT Chemicals.
Inventory	Inventory Inventory is stated at the lower of cost or net realizable value, with cost determined on a first-in first-out basis. The carrying value of inventory is reduced for estimated obsolescence. The Company evaluates the inventory carrying value for potential excess and obsolete inventory exposures by analyzing historical and anticipated demand. The following table sets forth the components of the Company’s inventory balances as of December 31: 2017 2016 Finished goods $ 22,753 $ 7,684 Raw materials 35,557 – Packaging supplies 4,231 – $ 62,541 $ 7,684
Fixed assets	Fixed Assets Fixed assets consist of furniture, fixtures and office equipment, vehicles and trailers, equipment and leasehold improvements that are stated at cost, less accumulated depreciation. Depreciation is provided in amounts sufficient to relate the cost of depreciable assets to earnings over their estimated service lives (3 – 10 years) under the straight-line method. Maintenance and repairs are charged to earnings as incurred; major repairs and replacements are capitalized. When items of property or equipment are sold or retired, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is included in operations. Property and equipment operated under material leases which transfer substantially all benefits and risks associated with the assets to the Company are capitalized. An asset and liability equal to the present or fair value, if appropriate, of minimum payments over the term of the leases are recorded. Depreciation of the asset is computed using the straight-line method over the life of the asset. Expenses associated with operating leases are charged to income as incurred.
Goodwill	Goodwill Goodwill represents the excess of the value of the purchase price and related costs over the identifiable assets from business acquisitions. The Company conducts an annual impairment assessment, at the reporting unit level, of its recorded goodwill. The Company assesses qualitative factors in order to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. The qualitative factors evaluated by the Company include: macro-economic conditions of the local business environment, overall financial performance, and other entity specific factors as deemed appropriate. If, through this qualitative assessment, the conclusion is made that it is more likely than not that a reporting unit’s fair value is less than its carrying amount, a two-step impairment test is performed. Management determined, by assessing the qualitative factors, that it is more likely than not that the fair value of the reporting unit is greater than its carrying value. Management does not consider the value of goodwill recorded for KT in the accompanying consolidated balance sheet to be impaired as of December 31, 2017. (see Note 10) The accompanying consolidated balance sheets, consolidated statements of operations, changes in stockholders’ equity (deficit) and cash flows include the results of operations of KT from the date of acquisition. Goodwill consists of the following: Goodwill at December 31, 2016 $ – Goodwill generated from acquisition of KT 2,294,952 Goodwill at December 31, 2017 $ 2,294,952
Share based compensation	Share-Based Compensation The Company recognizes compensation expense for all share-based payments in accordance with FASB Codification Topic 718, Compensation — Stock Compensation
Income Taxes	Income Taxes The Company accounts for Federal and state income taxes using the asset and liability approach for financial accounting and reporting for income taxes based on tax effects of differences between the financial statement and tax basis of assets and liabilities. The Company accounts for all uncertain tax positions in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification 740 – Income Taxes (“ASC 740”). ASC 740 provides guidance on de-recognition, classification, interest and penalties and disclosure related to uncertain income tax positions. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as a component of income tax expense. There were no accrued interest or penalties as of December 31, 2017 and 2016. From time to time, the Company may be audited by taxing authorities. These audits could result in proposed assessments of additional taxes. The Company believes that its tax positions comply in all material respects with applicable tax law. However, tax law is subject to interpretation, and interpretations by taxing authorities could be different from those of the Company, which could result in the imposition of additional taxes. The Company’s federal returns since 2014 are still subject to examination by taxing authorities.
Prepaid Expenses	Prepaid Expenses Prepaid expenses consist of expenses the Company has paid for prior to the service or good being provided. These prepaid expenses will be recorded as expense at the time the service has been provided.
License Fee	License Fee Effective December 31, 2016, the Company entered into an Exclusive Patent Licenses Agreement with CBI Polymers, Inc. ("CBI"), pursuant to which the Company would sell DeconGel ™
Going Concern	Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred substantial operating losses during 2017 and 2016 resulting in an accumulated deficit of $4,711,007 at December 31, 2017, and an accumulated deficit of $1,996,042 and a deficit in equity of $945,587 at December 31, 2016. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the financial statements are being issued. As such, the Company will need to arrange for additional financing to fully implement its business plan, including continued growth and establishment of a stronger brand. The Company is actively seeking growth of its service offerings, both organically and via new client relationships. In the ordinary course of the Company’s business, management is trying to raise additional capital through sales of common stock as well as seeking debt financing from third parties. There are no assurances that additional financing will be available on favorable terms, or at all. If additional financing is not available, the Company will need to reduce, defer or cancel development programs, planned initiatives and overhead expenditures. The failure to adequately fund its capital requirements could have a material adverse effect on the Company’s business, financial condition and results of operations, including potential discontinuance of operations. Moreover, the sale of additional equity securities to raise financing will result in additional dilution to the Company’s stockholders. Additionally, incurring additional indebtedness could involve an increased debt service cash obligation, as well as the imposition of covenants that restrict the Company’s operations or the Company’s ability to perform on its current debt service requirements. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements Pronouncements Recently Adopted In July 2015, the Financial Accounting Standards Board (“FASB”) issued an Accounting Standards Update (“ASU”) No. 2015-11, Simplifying the Measurement of Inventory In November 2015, the FASB issued ASU No. 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes In March 2016, the FASB issued ASU No. 2016-09, Compensation – Stock Compensation (Topic 718) Pronouncements Not Yet Adopted In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, In February 2016, the FASB issued ASU Update No. 2016-02, Leases (Topic 842) In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments - a consensus of the Emerging Issues Task Force certain transactions are classified in the statement of cash flows. Certain issues addressed in this guidance include - debt payments or debt extinguishment costs, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, distributions received from equity method investments and beneficial interests in securitization transactions. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. ASU 2016-15 is not expected to have a material impact on the Company’s consolidated financial statements. In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business ASU 2017-01 is not expected to have a material impact on the Company’s consolidated financial statements. In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill impairment On May 10, 2017, the FASB issued ASU No. 2017-09, Compensation–Stock Compensation (Topic 718): Scope of Modification Accounting

1. Summary of Significant Acc20

1. Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Schedule of inventory	2017 2016 Finished goods $ 22,753 $ 7,684 Raw materials 35,557 – Packaging supplies 4,231 – $ 62,541 $ 7,684
Schedule of goodwill	Goodwill at December 31, 2016 $ – Goodwill generated from acquisition of KT 2,294,952 Goodwill at December 31, 2017 $ 2,294,952

2. Accounts Receivable (Tables)

2. Accounts Receivable (Tables)	12 Months Ended
	Dec. 31, 2017
Receivables [Abstract]
Schedule of accounts receivable	2017 2016 Commissions receivable from KT (prior to acquisition) $ – $ 13,600 Trade receivables 49,603 – $ 49,603 $ 13,600

4. Notes Payable (Tables)

4. Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Future minimum principal payments	2018 $ 35,650 2019 37,251 2020 34,292 2021 2,119 2022 and thereafter – $ 109,312

5. Accrued Expenses (Tables)

5. Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2017
Payables and Accruals [Abstract]
Schedule of accrued expenses	2017 2016 Professional Fees $ – $ 38,000 Other Accrued Expenses 19,949 1,022 $ 19,949 $ 39,022

6. Income Taxes (Tables)

6. Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Reconciliation of income tax rate	2017 2016 Tax benefit calculated at statutory rate 21% 34% Expense not deductible (.19 ) (0.15 ) Changes to valuation allowance (11.29 ) (33.85 ) Effect of U. S. Statutory rate changes (9.52 ) – Provision for income taxes –% –%
Schedule of deferred tax assets and liabilities	2017 2016 Net non-current deferred tax assets: Net operating loss carry-forward $ 1,036,096 $ 675,696 Fixed assets 24,079 – Net non-current deferred tax liabilities: Intangible assets (10,841 ) – Net 1,049,333 675,696 Less valuation allowance (1,049,333 ) (675,696 ) Net deferred taxes $ – $ –

8. Stockholders' Equity (Tables

8. Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Schedule of option activity	Shares Under Option Price Per Share Weighted Average Exercise Price Weighted Average Remaining Contractual Life Outstanding - beginning of year – $ – $ – Granted 3,566,418 $ 0.00 - 1.50 $ 0.39 Exercised 126,668 $ 1.50 $ 1.50 Canceled or expired – – – Outstanding - end of year 3,439,750 $ 0.00 - 1.50 $ 0.39 113 months Exercisable - end of year 2,827,417 $ 0.42 113 months
Assumptions for option valuation	2017 Expected life – years 3.25 – 10 Interest rate 1.50 - 2.48 % Volatility 71.70 % Dividend yield – %

10. Business Acquisition (Table

10. Business Acquisition (Tables)	12 Months Ended
	Dec. 31, 2017
Business Combinations [Abstract]
Total consideration paid for acquisition	Total consideration $ 2,707,800 The assets acquired and liabilities assumed were as follows: Assets acquired: Cash $ 21,046 Inventory 38,500 Accounts receivable 40,434 Property and equipment, net 458,079 Total tangible assets 558,059 Liabilities assumed: Accounts payable 28,932 Accrued expenses 11,693 Capital lease 104,586 Total liabilities 145,211 Net acquired assets 412,848 Goodwill 2,294,952 Total $ 2,707,800
Proforma information	Pro Forma Information (unaudited) December 31, 2017 December 31, 2016 Revenues $ 1,179,456 $ 755,660 Net loss $ (2,783,694 ) $ (2,234,996 ) Loss per share $ (.31 ) $ (.48 )

Nature of Business (Details Nar

Nature of Business (Details Narrative)	Feb. 15, 2017
KT Chemicals, Inc. [Member]
Equity ownership	100.00%

1. Summary of Significant Acc28

1. Summary of Significant Accounting Policies (Details - Goodwill)	12 Months Ended
	Dec. 31, 2017USD ($)
Accounting Policies [Abstract]
Goodwill beginning balance	$ 0
Goodwill additions	2,294,952
Goodwill ending balance	$ 2,294,952

1. Summary of Significant Acc29

1. Summary of Significant Accounting Policies (Details - Inventory) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Accounting Policies [Abstract]
Finished goods	$ 22,753	$ 7,684
Raw materials	35,557	0
Packaging supplies	4,231	0
Total inventory	$ 62,541	$ 7,684

1. Summary of Significant Acc30

1. Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Allowance for doubtful accounts	$ 0	$ 0
Accumulated deficit	(4,711,007)	(1,996,042)
Stockholders' equity	$ 2,953,305	$ (945,587)	$ (80,251)
Warrants [Member]
Antilutive shares	1,110,000	2,885,000
Options [Member]
Antilutive shares	3,439,750	0

2. Accounts Receivable (Details

2. Accounts Receivable (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Receivables [Abstract]
Commissions receivable	$ 0	$ 13,600
Trade receivables	49,603	0
Total accounts receivable	$ 49,603	$ 13,600

3. Due To_From CBI (Details Nar

3. Due To/From CBI (Details Narrative) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
License fees payable	$ 4,463	$ 1,667

4. Notes Payable (Details - Fut

4. Notes Payable (Details - Future debt maturities)	Dec. 31, 2017USD ($)
Debt Disclosure [Abstract]
Future minimum principal payment 2018	$ 35,650
Future minimum principal payment 2019	37,251
Future minimum principal payment 2020	34,292
Future minimum principal payment 2021	2,119
Future minimum principal payment 2022	0
Future minimum principal payments	$ 109,312

4. Notes Payable (Details Narra

4. Notes Payable (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Debt outstanding	$ 35,650	$ 900,187
Stock issued conversion of note, stock value	3,614,760	1,050,047
Repayment of notes payable	$ 1,575,189	262,500
KT Chemicals, Inc. [Member]
Debt issuance date	Feb. 15, 2017
Debt maturity date	Dec. 31, 2017
Debt face amount	$ 2,700,000
Debt outstanding	$ 0
Convertible Promissory Notes 1 [Member]
Debt face amount		$ 1,010,000
Debt converted, shares issued		2,737,393
Stock issued conversion of note, stock value		$ 1,050,047
CBI [Member]
Debt issuance date	Oct. 5, 2016
Debt stated interest rate	12.00%
Debt maturity date	Jun. 30, 2017
Debt face amount		494,919
Debt default interest rate	15.00%
Debt outstanding	$ 0	509,076
Convertible Promissory Notes 2 [Member]
Debt maturity date	Jun. 30, 2017
Debt face amount		385,000
Debt default interest rate	15.00%
Debt outstanding	$ 0	391,111
Convertible Promissory Notes 2 [Member] | 1st Quarter 2017 [Member]
Debt stated interest rate	6.00%
Debt maturity date	Dec. 31, 2017
Debt face amount	$ 1,900,000
Proceeds from convertible notes	$ 1,900,000
Convertible Promissory Notes 2 [Member] | 2nd Quarter 2017 [Member]
Debt stated interest rate	6.00%
Debt maturity date	Dec. 31, 2017
Debt face amount	$ 600,000
Proceeds from convertible notes	$ 600,000
Convertible Notes Payable [Member]
Debt converted, shares issued	3,877,931
Debt converted, amount converted	$ 3,631,460
Vehicles and Equipment [Member]
Debt outstanding	$ 109,312	$ 0
Interest rate terms	3.95% to 5.99%
Maturity dates	July 2020, December 2020 and February 2021

5. Accrued Expenses (Details)

5. Accrued Expenses (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Payables and Accruals [Abstract]
Professional fees	$ 0	$ 38,000
Other accrued expenses	19,949	1,022
Total accrued expenses	$ 19,949	$ 39,022

6. Income Taxes (Details - Tax

6. Income Taxes (Details - Tax percent)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Tax benefit calculated at statutory rate	21.00%	34.00%
Expense not deductible	(0.19%)	(0.15%)
Changes to valuation allowance	(11.29%)	(33.85%)
Effect of U. S. Statutory rate changes	(9.52%)	0.00%
Provision for income taxes	0.00%	0.00%

6. Income Taxes (Details - Defe

6. Income Taxes (Details - Deferred taxes) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Net operating loss carry-forward	$ 1,036,096	$ 675,696
Fixed assets	24,079	0
Intangible assets	(10,841)	0
Net	1,049,333	675,696
Less valuation allowance	(1,049,333)	(675,696)
Net deferred taxes	$ 0	$ 0

6. Income Taxes (Details Narrat

6. Income Taxes (Details Narrative)	12 Months Ended
	Dec. 31, 2017USD ($)
Income Tax Disclosure [Abstract]
Operating loss carryforward	$ 4,933,788
Operating loss carryforward expiration date	Dec. 31, 2035
Change in valuation allowance	$ 373,637

7. Commitments, Contingencies39

7. Commitments, Contingencies and Concentrations (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Lease expense	$ 99,750	$ 23,512
Sales Revenue Net [Member]
Concentration risk percentage		100.00%

8. Stockholders' Equity (Detail

8. Stockholders' Equity (Details - Option activity)	12 Months Ended
	Dec. 31, 2017$ / sharesshares
Equity [Abstract]
Options outstanding, beginning balance | shares	0
Options granted | shares	3,566,418
Options exercised | shares	126,668
Options canceled or expired | shares	0
Options outstanding, ending balance | shares	3,439,750
Options exercisable | shares	2,827,417
Price per share, options granted	$0.00-$1.50
Price per share, options exercised	$ 1.50
Price per share, options outstanding, ending	$0.00 - $1.50
Weighted average exercise price, beginnning | $ / shares
Weighted average exercise price, options granted | $ / shares	0.39
Weighted average exercise price, options exercised | $ / shares	1.50
Weighted average exercise price, options expired | $ / shares
Weighted average exercise price, options outstanding ending | $ / shares	0.39
Weighted average exercise price, options exercisable | $ / shares	$ 0.42
Weighted average remaining contractual life, outstanding	113 months
Weighted average remaining contractual life, exercisable	113 months

8. Stockholders' Equity (Deta41

8. Stockholders' Equity (Details - Option valuation)	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Expected life in years	3.25-10 years
Interest rate - minimum	1.50%
Interest rate - maximum	2.48%
Volatility	71.70%
Dividend yield

8. Stockholders' Equity (Deta42

8. Stockholders' Equity (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Warrants exercised	2,375,000
Proceeds from warrants exercised	$ 1,187,500
Warrants outstanding	1,110,000	2,885,000
Share based compensation	$ 709,597
Unamortized share-based compensation	$ 10,548
Unamortized share-based compensation term	20 months
2016 Stock Option Plan [Member]
Options authorized under plan	3,750,000
Consultant [Member]
Warrants issued	600,000
Warrant expiration date	Mar. 31, 2024
Fair value of warrants	$ 302
Warrants [Member] | Notes Payable [Member]
Warrants issued	2,885,000
Warrant expiration date	Dec. 31, 2018
Fair value of warrants	$ 0

9. Related Party Transactions (

9. Related Party Transactions (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Three Shareholders [Member]
Consulting fees	$ 299,710
Due to related parties	77,000
Maine Consultants [Member]
Consulting fees		$ 21,503
Former executive and current shareholder [Member]
Consulting fees		80,000
Due to related parties	$ 25,000	$ 80,000

10. Business Acquisition (Detai

10. Business Acquisition (Details - Acquisition) - USD ($)	12 Months Ended
	Dec. 31, 2017	Feb. 15, 2017	Dec. 31, 2016
The assets acquired and liabilities assumed were as follows:
Goodwill	$ 2,294,952		$ 0
KT Chemicals, Inc. [Member]
Total consideration	$ 2,707,800
The assets acquired and liabilities assumed were as follows:
Cash		$ 21,046
Inventory		38,500
Accounts receivable		40,434
Property and equipment, net		458,079
Total tangible assets		558,059
Accounts payable		28,932
Accrued expenses		11,693
Notes payable		104,586
Total liabilities		145,211
Net acquired assets		412,848
Goodwill		2,294,952
Total		$ 2,707,800

10. Business Acquisition (Det45

10. Business Acquisition (Details - Pro Forma) - KT Chemicals, Inc. [Member] - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Pro forma revenues	$ 1,179,456	$ 755,660
Pro forma net loss	$ (2,783,694)	$ (2,234,996)
Pro forma loss per share	$ (0.31)	$ (0.48)

10. Business Acquisition (Det46

10. Business Acquisition (Details Narrative)	12 Months Ended
	Dec. 31, 2017USD ($)shares
Stock issued for acquisition, value	$ 7,800
KT Chemicals, Inc. [Member]
Cash paid for acquisition	$ 2,700,000
Stock issued for acquisition, shares | shares	520,000
Stock issued for acquisition, value	$ 7,800